IMMUNOCORE HLDGS ADS/1 (6YG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-32.66 Million ≈ $-38.18 Million USD) by net assets (€381.03 Million ≈ $445.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IMMUNOCORE HLDGS ADS/1 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does IMMUNOCORE HLDGS ADS/1 carry for a breakdown of total debt and financial obligations.
IMMUNOCORE HLDGS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enovis Corp
NYSE:ENOV
|
0.059x |
|
Nanfang Pump Industry
SHE:300145
|
0.063x |
|
Red Cat Holdings Inc
NASDAQ:RCAT
|
-0.148x |
|
Genimous Technology Co Ltd
SHE:000676
|
0.013x |
|
Xiamen Kingdomway Group Co
SHE:002626
|
0.040x |
|
CTS Corporation
NYSE:CTS
|
0.053x |
|
Reysas Gayrimenkul Yatirim Ortakligi AS
IS:RYGYO
|
0.012x |
|
Shenzhen Jame Technology Corp Ltd
SHE:300868
|
0.013x |
Annual Cash Flow Conversion Efficiency for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual cash flow conversion efficiency of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see IMMUNOCORE HLDGS ADS/1 market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €381.03 Million ≈ $445.47 Million |
€-10.71 Million ≈ $-12.52 Million |
-0.028x | -138.91% |
| 2024-12-31 | €360.72 Million ≈ $421.71 Million |
€26.06 Million ≈ $30.47 Million |
0.072x | +806.40% |
| 2023-12-31 | €368.84 Million ≈ $431.22 Million |
€2.94 Million ≈ $3.44 Million |
0.008x | +105.49% |
| 2022-12-31 | €338.90 Million ≈ $396.21 Million |
€-49.21 Million ≈ $-57.53 Million |
-0.145x | -- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more